

***In Vitro* Anti-skin Cancer Properties and Mechanisms of Action of Xanthones from the Mangosteen Pericarp**

A thesis submitted in fulfillment of the requirement for the degree of
Doctor of Philosophy

By

Jing Jing WANG

Bachelor of Clinical Medicine

Department of Medical Biotechnology

School of Medicine

Faculty of Health Sciences

Flinders University of South Australia

September 2012

Candidate's Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

Jing Jing Wang

September 2012

Thesis Summary

The incidence of skin cancer has increased more than 600% worldwide since the 1940s, and Australians have the highest incidence in the world, with at least 2 in 3 Australians diagnosed with skin cancer before the age of 70. The current chemotherapy is not effective, with new drugs in high demand. Plants are important sources for anti-cancer drugs. Mangosteen (*Garcinia mangostana* Linn.) is a tropical tree from South East Asia and its fruit pericarp is a well-known traditional medicine.

This study investigated the potential anti-skin cancer activity of the crude extract and major xanthone compounds from the pericarp of mangosteen by investigating the cytotoxicity and underlying cellular and molecular mechanisms. Two types of human skin cancer cell lines were used as *in vitro* models: melanoma SK-MEL-28 and squamous cell carcinoma A-431.

There were five major research outcomes. (i) Development of a methodology for extraction of mangosteen based on chemical composition and antioxidant activity. (ii) Demonstration of anti-proliferative activity towards skin cancer cell lines. The crude extract and six xanthone compounds tested had significant anti-cancer activities, with IC_{50} values ranging from 2.39 to 7.61 $\mu\text{g/ml}$. The activity was selective against skin cancer cells with less effect on human normal skin fibroblast CCD-1064Sk and the keratinocyte HaCaT cell lines. IC_{50} values of the xanthenes were similar to, or much lower than, those of two most commonly used commercial drugs (5-fluorouracil and dacarbazine). (iii) Identification of cellular and molecular pathways. The anti-cancer action of xanthone compounds was found to be via activation of caspases together with the loss of mitochondrial membrane potential

and inhibition of Akt and NF κ B survival pathways. In melanoma SK-MEL-28 cells, downregulation of BRAF V600E mutation expression was observed after treatment with some xanthenes, e.g. a maximum 6.8-fold decrease in the level of BRAF V600E relative to the untreated control. (iv) Identification of synergistic effects. Synergistic effects between α -mangostin and the other individual compounds were observed. However, no synergistic effect was found between xanthone compounds and commercial drugs under the tested conditions in the current study. (v) Evaluation of anti-metastatic activity of α -mangostin. Skin cancers, especially melanoma, have a high potential to metastasise. α -Mangostin exhibited significant inhibitive activity of invasion and migration at non-toxic doses on both skin cancer cell lines tested. The anti-metastatic activity of α -mangostin was associated with downregulation of mRNA expression of MMP-2 and MMP-9 through inhibiting NF κ B and Akt pathways.

This study provides important scientific evidence of the potential antioxidant and antiproliferative activity of extracts and xanthone compounds from the pericarp of mangosteen, and increases understanding of their underlying mechanisms. These findings can contribute to the development of novel plant-derived antioxidant strategies in the treatment of skin cancers.

Keywords: skin cancer; mangosteen; xanthenes; cytotoxicity; apoptosis; survival pathway; metastasis

Acknowledgements and Dedication

First and foremost, I would like to pay principal acknowledgement to my supervisors, Prof. Wei Zhang and Dr. Barbara Sanderson, for their very great help in supervision of the project, my PhD candidature and the laboratory.

Thank you, Wei, your concern for my project, career, and professional development provided the perfect role model for an all-round mentor and advisor, and for your encouragement of critical thinking and your high expectations of me.

Thank you, Barbara, for your continuous support, assistance, advice and perspective, especially your help with improving my scientific writing, at various points throughout my candidature. I am very grateful that I could always count on you whenever I needed your help.

Thank you goes to all past and present members of the Department of Medical Biotechnology for assistance with experiments, for advice, and for their companionship. In particular, I would like to thank Professor Chris Franco, for his care and concern, in helping me to get through a difficult time. I wish to directly thank Mrs. Angela Binns and Mrs. Barbara Kupke. Without their continuous and generous help, I could not have completed my project so quickly and smoothly.

Thank you, Niki Sperou, for your interest in my project and your help with my slides; Julian Adams, for your help with everything and your sense of humour; Jeff Barrett, for spending time with me to refine my presentation slides. I further thank Onuma Kaewkla, Tanya Bernardo, Vicki Edwards, Hao Jiang, Peng Su, Fitri Widi, Liufei Tan, Shuang Peng, Mahnaz Ramezanzpour, Xuelian Zhao, and Shan He for

their friendship. While there is not nearly enough room to mention you all, I believe you know that you all contributed to my completion.

Thank you, Dr. George Mayne, for guiding me in the use and analysis of real-time PCR; Mrs. Sheree Bailey and Mr. Eugene Ng for their helpful assistance with Flow cytometry; Mrs. Monica Dreimanis for her continuous help with cell culture techniques; and Dr. Jennifer Clark for her kind assistance with microscopy and image analysis.

Special thank you goes to Dr. He Wang, for the opportunity that he offered me to come to Australia to work as a research assistant and start my research career.

Personal thanks go first to my husband Lixin Li, my parents and my sister. Their patience, love, understanding and assistance enabled me to perform at my best. Thanks to Mrs Ilze Thomas, who has already become like one of my family, for her care, help, and friendship in the past years, and especially for her correction of my thesis in my final stage of PhD. Thanks to all my friends whose company and support kept me going over these years.

In memory of my special close friend, Mrs. Alita Larsens.

List of Abbreviations

%	Percentage
AAPH	2, 2'-Azobis (2-amidinopropane) dihydrochloride
Akt	Protein kinase B
ANOVA	Analysis of Variance
ATCC	American type culture collection
AU	Arbitrary unit
BRAF	Serine/threonine-protein kinase <i>B-Raf</i>
BSA	Bovine serum albumin
°C	Degree celcius
CDK	Cyclin-dependent kinases
CKI	Cyclin-dependent kinases inhibitors
COX-2	Cyclooxygenase-2
Ct	Threshold of cycle
DAPI	4', 6-Diamidino-2-phenylindole dihydrochloride
DMBA	7,12-dimethyl[a]benzanthracene
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	Dimethyl sulfoxide
DPPH	2, 2-Diphenyl-1-picrylhydrazyl
%DRSA	Percentage DPPH radical scavenging activity
DTIC	Dacarbazine
DW	Dry weight
EMA	European agency for the evaluation of medicinal products
ECM	Extracellular matrix
EDTA	Ethylenediaminetetraacetic acid
ERK	Extracellular signal-regulated kinase
EtOH	Ethanol
FAK	Focal adhesion kinase
FBS	Foetal bovine serum
FDA	Food and drug administration
FRAP	Ferric reducing antioxidant power
5-FU	5-Fluorouracil
µg	Microgram
GAE	Gallic acid equivalents
GOI	Gene of interest
h	hour
HCl	Hydrochloric acid
HPLC	High performance liquid chromatography
HO ⁻	Hydroxide ion
IC ₅₀	50% inhibitory concentration
IκB	Inhibitor of kappaB
IKK	IκB kinase
IL-8	Interleukin-8
IMDM	Iscoves Modified Dulbecco's Medium
IU	International units
JNK	c-Jun NH ₂ -terminal kinase
l	litre
LDL	Low density lipoprotein
µl	microlitre

μM	micromolar
ml	millilitre
MAPK	Mitogen-activated protein kinase
MMP	Matrix metalloproteinase
MPEE	Mangosteen pericarp ethanol extract
MPWE	Mangosteen pericarp water extract
MQ	Milli Q
mRNA	Messenger ribonucleic acid
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
NFκB	Nuclear factor kappa B
NSAIDS	Nonsteroidal antiinflammatory drugs
OD	Optical density
ORAC	Oxygen radical absorbance capacity
PBS	Phosphate-buffered saline
ONOO ⁻	Peroxynitrite
PCR	Polymerase chain reaction
PI	Propidium iodide
PI3K	Phosphoinositide 3-kinase
qRT-PCR	Quantitative real-time reverse transcription PCR
ROS	Reactive oxygen species
RPMI	Roswell Park Memorial Institute
R ²	R square
RT	Room temperature
s	second
SD	Standard deviation
SDS	Sodium Dodecyl Sulfate
SEM	Standard error of the mean
SPSS	Statistical Package for the Social Sciences
TE	Trolox equivalents
TF	Total flavonoids
TNF	Tumor necrosis factor
TP	Total phenolics
TPA	12-O-tetradecanoylphorbol-13-acetate
TRAP	Total radical trapping antioxidant parameter
UCA	Urocanic acid
uPA	Urokinase-type plasminogen activator
UV	Ultraviolet
VEGF	Vascular endothelial growth factor

Publications, Presentations and Awards

Publications

- Jing J. Wang, Barbara J.S. Sanderson, Wei Zhang, 2011. Cytotoxic effect of xanthenes from pericarp of the tropical fruit mangosteen (*Garcinia mangostana* Linn.) on human melanoma cells. *Food and Chemical Toxicology*. 49: 2385–2391
- Jing J. Wang, Barbara J.S. Sanderson, Wei Zhang, 2012. Significant anti-invasive activities of α -mangostin on metastasis of human skin cancer cells. *Anticancer Research* (Article in press)
- Jing J. Wang, Qing H. Shi, Wei Zhang, Barbara J.S. Sanderson, 2012. Anti-skin cancer properties of phenolic-rich extract from the pericarp of mangosteen (*Garcinia mangostana* Linn.). *Food and Chemical Toxicology*. 50: 3004-3013.

Publications in Submission

- Jing J. Wang, Wei Zhang, Barbara J.S. Sanderson, 2012. Altered mRNA expression related to the apoptotic effect of three xanthenes on human melanoma SK-MEL-28 cell line. *Food and Chemical Toxicology* (Under review; manuscript No. FCT-6676).

Publications in preparation

- Jing J. Wang, Barbara J.S. Sanderson, Wei Zhang. Anti-proliferative and apoptotic effect of 6 pure xanthone compounds on human squamous cell carcinoma A-431 cells.
- Jing J. Wang, Wei Zhang, Barbara J.S. Sanderson. Xanthenes isolated from mangosteen pericarp induce apoptosis in human melanoma SK-MEL-28 cells.
- Jing J. Wang, Barbara J.S. Sanderson, Wei Zhang. Potential synergistic skin cancer suppression by combination of xanthenes.

Presentations

- ASMR SA Scientific Meeting 6th June 2012. Adelaide, Australia. Oral Presentation "Inhibitory effect of α -mangostin on proliferation and metastasis of human melanoma SK-MEL-28 cell line"
- Cancer Research Day. 25th November 2011. Adelaide, Australia. Oral Presentation. "Xanthenes from mangosteen pericarp: anti-skin cancer properties"
- AusBiotech 2011 National Conference. 16th -19th October 2011. Adelaide, Australia. Oral and Poster Presentation "*In vitro* anti-skin cancer properties and mechanisms of action of α -mangostin from the mangosteen pericarp"
- Asian Congress on Biotechnology. 11th-15th May 2011. Shanghai, China.

Poster Presentation. “Anti-skin cancer activity of crude extract of mangosteen (*Garcinia mangostana* Linn.)”

- Three Minute Thesis Competition 2011. 6th May 2011. Adelaide, Australia. Oral Presentation “Mangosteen combats skin cancer”
- Chemeca 2010. 26th -29th September 2010. Adelaide, Australia. Oral Presentation “Compounds from pericarp of mangosteen (*Garcinia Mangostana* Linn.) induce cell cycle arrest and apoptosis in human melanoma cells”
- 13th World Congress on Cancers of the Skin. 7th -10th April 2010. Madrid, Spain. Oral Presentation “Evaluation of antiproliferation properties of xanthenes from pericarp of mangosteen (*Garcinia mangostana* L.) on human melanoma cells”

Awards

- 2012 Ross Wishart Memorial Award finalist
- 2011 AusBiotech-GSK Student Excellence Award – State Winner
- 2011 Chinese Government Award for Outstanding Self-financed Students Abroad
- 2010 “Top Ten Cited Author in 2007 & 2008” from Mutation Research
- 2010 AusBiotech-GSK Student Excellence Award – State Finalist
- 2008 AusBiotech-GSK Student Excellence Award – State Finalist
- 2008 – 2012 EPRIS Scholarship, Flinders University, Australia

Professional Membership

- 2010- current AusBiotech (Australia’s Biotechnology Organisation)
- 2012 – 2013 Australian Society for Medical Research
- 2012-2013 Bioprocessing Network

Table of Content

Candidate's Declaration.....	i
Thesis Summary	ii
Acknowledgements and Dedication	iv
List of Abbreviations	vi
Publications, Presentations and Awards	viii
Professional Membership	ix
Table of Content	x
List of Tables	xvi
List of Figures.....	xvii
Chapter 1 INTRODUCTION AND LITERATURE REVIEW	1
1.1 Skin cancer.....	2
1.1.1 The skin	2
1.1.2 Major types of skin cancers.....	2
1.1.3 Epidemiology of skin cancer.....	3
1.1.4 Ultraviolet (UV) radiation, antioxidants, and skin cancers	4
1.1.4.1 UV and skin cancers	4
1.1.4.2 Antioxidants and UV-induced skin cancers.....	7
1.1.5 Skin cancer development.....	8
1.1.6 Current strategies for skin cancer prevention and therapies and their limitations	9
1.1.6.1 Skin cancer prevention.....	9
1.1.6.2 Skin cancer therapies	11
1.1.7 Therapeutic strategies for skin cancers	12
1.1.7.1 Targeting deregulation of cell cycle.....	13
1.1.7.2 Targeting resistance to apoptotic cell death.....	17
1.1.7.3 Targeting activation of survival pathways.....	21
1.1.7.4 Targeting activation of invasion and metastasis	24
1.2 The role of plant-derived natural products in skin cancer treatment and prevention	27
1.2.1 Chemopreventive activity of plant secondary metabolites in skin cancers	27
1.2.2 Cytotoxicity of plant secondary metabolites in skin cancers	31
1.2.3 Anti-metastatic effect of plant secondary metabolites in skin cancers	37
1.3 <i>Garcinia mangostana</i> Linn.....	40
1.3.1 Botanical description.....	40
1.3.2 Traditional medical properties.....	41
1.3.3 Xanthones in the mangosteen and their chemical structures.....	41
1.3.4 Biological activities of extracts and pure compounds derived from mangosteen	50
1.3.4.1 Antioxidant effect of mangosteen	50
1.3.4.2 Cytotoxicity of mangosteen towards cancer cells.....	54
1.3.4.3 Inhibition of metastasis	64
1.3.4.4 Other effects.....	68
1.4 Hypotheses.....	68
1.5 Thesis scope and aims	69
1.6 Significance	72

Chapter 2	Optimisation of the Extraction Methods and Characterisation of the Antioxidant Properties of Mangosteen Pericarp Extracts	73
2.1	Introduction.....	74
2.2	Materials and methods.....	77
2.2.1	Materials.....	77
2.2.2	Preparation of mangosteen pericarp.....	77
2.2.3	Mangosteen pericarp extraction methods.....	78
2.2.4	Preparation of green tea extract.....	79
2.2.5	Chemical profile characterisation of mangosteen pericarp extracts.....	79
2.2.5.1	Total Phenolics (TP) analysis	79
2.2.5.2	Total flavonoid (TF) analysis.....	80
2.2.5.3	High performance liquid chromatography (HPLC) profile of mangosteen pericarp extracts	80
2.2.6	Antioxidant assays.....	81
2.2.6.1	DPPH radical scavenging activity.....	81
2.2.6.2	Ferric reducing antioxidant power (FRAP) assay.....	82
2.2.6.3	Oxygen radical absorbance capacity (ORAC) assay	82
2.2.7	Preparation of extracts for biological assays.....	83
2.2.8	Statistical analysis	84
2.3	Results.....	84
2.3.1	The mangosteen pericarp.....	84
2.3.2	Optimisation of extraction method.....	84
2.3.2.1	Effect of the extraction temperature.....	85
2.3.2.2	Effect of the pericarp/solvent ratio.....	85
2.3.2.3	Effect of the extraction duration	85
2.3.2.4	Effect of solvent concentration for MPEE.....	85
2.3.2.5	Optimal extraction conditions.....	87
2.3.3	Yield of extracts	87
2.3.4	Chemical profile characterisation of mangosteen pericarp extract	87
2.3.4.1	TP and TF contents	87
2.3.4.2	HPLC profile of mangosteen pericarp extracts.....	88
2.3.5	Antioxidant properties of the mangosteen pericarp extract.....	90
2.4	Discussion.....	90
2.4.1	Optimisation of the extraction methods	90
2.4.2	Antioxidant properties of the mangosteen pericarp extract.....	93
2.5	Summary.....	96
Chapter 3	Cytotoxic Effect of Crude Mangosteen Pericarp Extracts and Pure Xanthenes on Human Skin Cell Lines.....	98
3.1	Introduction.....	99
3.2	Materials and methods.....	100
3.2.1	Materials.....	100
3.2.2	Cell lines and cell culture	101
3.2.2.1	Cell lines	101
3.2.2.2	Cell morphology	101
3.2.2.3	Cell culture.....	102
3.2.2.4	Cell doubling time.....	105
3.2.3	Treatment preparation	106
3.2.4	Trypan Blue exclusion assay.....	106
3.2.5	Cell proliferation assays	107
3.2.5.1	MTT Assay	107

3.2.5.2	Crystal Violet assay	108
3.2.5.3	Standard curves for the MTT assay and Crystal Violet assay	108
3.2.6	Statistical analysis	109
3.3	Results.....	109
3.3.1	Optimisation of cell adherence time and cell density per well.....	109
3.3.1.1	Cell adherence time.....	109
3.3.1.2	Cell density seeded per well.....	111
3.3.2	Comparison of MTT assay and the Crystal Violet assay	114
3.3.2.1	Standard curves	114
3.3.2.2	Cell viability.....	115
3.3.2.3	Intra- and inter-assay coefficients of variance (CV).....	118
3.3.2.4	Summary of comparison of the MTT and Crystal Violet assays	118
3.3.3	Cytotoxicity of crude extracts and pure xanthone compounds from the mangosteen pericarp on human skin cells	119
3.3.3.1	Cellular morphological changes with or without treatment with xanthoness	119
3.3.3.2	Cytotoxicity of MPEE and MPWE on human skin cancer cell lines	121
3.3.3.3	Cytotoxicity of MPEE on human normal skin cell lines	122
3.3.3.4	Cytotoxicity of pure xanthone compounds on human skin cancer and normal cell lines.....	123
3.3.3.5	Cytotoxicity of commercial drugs on human skin cell lines.....	124
3.4	Discussion.....	126
3.4.1	Cytotoxicity of crude extracts	126
3.4.2	Cytotoxicity of tested xanthone pure compounds	127
3.4.3	Cytotoxicity against cancer cells induced by MPEE and xanthoness..	128
3.4.4	Competitive advantage over the tested commercial drugs.....	129
3.4.5	Potential synergistic effect among individual xanthoness	130
3.4.6	Structure-related cytotoxicity	130
3.5	Summary	131
Chapter 4 Underlying Mechanisms of Cytotoxic Effects of Crude Extract and Pure Xanthone Compounds		132
4.1	Introduction.....	133
4.2	Materials and methods.....	134
4.2.1	Materials	134
4.2.2	Cell lines and cell culture	134
4.2.3	Cell cycle analysis	134
4.2.4	Apoptosis analysis.....	135
4.2.5	Caspase 3/7, 8 and 9 assays.....	136
4.2.6	Mitochondrial membrane potential ($\Delta\Psi_m$) detection	137
4.2.7	General methods for quantitative Real-time reverse transcription PCR (qRT-PCR).....	137
4.2.7.1	Primer preparation for qRT-PCR.....	137
4.2.7.2	Total RNA extraction.....	140
4.2.7.3	Quantification of RNA concentration	140
4.2.7.4	Verification of RNA integrity	140
4.2.7.5	Removal of DNA contamination	141
4.2.7.6	Reverse transcription of total RNA to cDNA	141
4.2.7.7	Validation of qRT-PCR	142
4.2.7.8	qRT-PCR reactions	146

4.2.8	Statistical analysis	147
4.3	Results.....	148
4.3.1	Effect of xanthenes on cell cycle in human skin cancer cells.....	148
4.3.2	Effect of xanthenes on apoptosis induction in human skin cancer cells	152
4.3.3	Effect of xanthenes on caspase activities in human skin cancer cells	155
4.3.3.1	Caspase 3/7 activities	155
4.3.3.2	Caspase 8 activities	155
4.3.3.3	Caspase 9 activities	156
4.3.4	Effect of xanthenes on mitochondrial membrane potential ($\Delta \Psi_m$) in human skin cancer cells	160
4.3.5	Modulation of gene expressions involved in cytotoxicity induced by xanthenes in human skin cancer cells.....	162
4.3.5.1	Modulation of cell cycle-related genes	162
4.3.5.2	Modulation of apoptosis-related genes	164
4.3.5.3	Modulation of genes in survival pathways	166
4.4	Discussion.....	171
4.4.1	Cell cycle modulatory effect of xanthenes and the molecular mechanisms in human skin cancer cells	171
4.4.2	Apoptotic effect of xanthenes and the cellular and molecular pathways in human skin cancer cells	173
4.4.2.1	Apoptosis-inducing activity of xanthenes in human skin cancer cells	173
4.4.2.2	Mechanisms of xanthone-induced apoptosis	174
4.4.3	Modulation of genes in survival pathways.....	179
4.4.4	General discussion of the variation of results	184
4.5	Summary.....	185
Chapter 5 Potential Synergistic Effects of combining xanthenes with commercial drugs or with α-mangostin.....		187
5.1	Introduction.....	188
5.2	Materials and Methods	189
5.2.1	Materials.....	189
5.2.2	Crystal Violet assay.....	189
5.2.3	Cell cycle analysis and apoptosis analysis	190
5.2.4	Experimental design for screening of potential synergistic cytotoxic effect	190
5.2.4.1	Combinations of xanthenes with commercial drugs (5-FU & DTIC)	190
5.2.4.2	Combinations of α -mangostin with individual xanthone compounds	190
5.2.5	Statistical analysis	191
5.3	Results.....	192
5.3.1	Combinations with commercial drugs.....	192
5.3.2	Combinations of α -mangostin with another xanthone compound	194
5.3.2.1	Effects of combinations of α -mangostin with another xanthone on human squamous cell carcinoma A-431 cells	194
5.3.2.2	Effects of combinations α -mangostin with another xanthone on human melanoma SK-MEL-28 cells.....	198
5.3.3	Potential mechanisms of observed synergistic effects	203
5.3.3.1	The modulatory effect on cell cycle regulation after treatment with	

combination of α -mangostin with another xanthone in skin cancer cells	203
5.3.3.2 Apoptosis-inducing effect after treatment with combinations of α -mangostin with another xanthone in skin cancer cells.....	206
5.4 Discussion.....	208
5.4.1 No synergy observed when xanthones in combination with commercial drugs	208
5.4.2 Synergy found between α -mangostin and another xanthone in inhibiting skin cancer cell proliferation	210
5.5 Summary	212
Chapter 6 Anti-metastatic effect of α-mangostin on human skin cancer cells....	213
6.1 Introduction.....	214
6.2 Materials and methods.....	215
6.2.1 Materials	215
6.2.2 Cell lines and cell culture	216
6.2.3 Treatment preparation	216
6.2.4 Cell viability assay	216
6.2.5 Wound healing Assay.....	216
6.2.6 Boyden chamber invasion and migration assay	217
6.2.7 Cell-matrix adhesion assay.....	218
6.2.8 Real-time polymerase chain reaction (qRT-PCR).....	218
6.2.9 Statistical analysis	219
6.3 Results.....	219
6.3.1 α -Mangostin inhibits the motility of skin cancer cells	219
6.3.2 α -Mangostin inhibits the migration and invasion of skin cancer cells.....	222
6.3.3 α -Mangostin inhibits the adhesion of skin cancer cells.....	225
6.3.4 α -Mangostin modulates the metastasis-related genes of skin cancer cells	227
6.4 Discussion.....	229
6.4.1 Inhibition of skin cancer cell motility, migration and invasion by α - mangostin.....	230
6.4.2 Inhibition of skin cancer cell adhesion by α -mangostin.....	230
6.4.3 Inhibition of mRNA expression of MMP-2 and MMP-9 by α - mangostin.....	231
6.4.4 Inhibition of NF κ B, Akt1, and BRAF V600E involved in the anti- metastatic activity induced by α -mangostin.....	232
6.5 Summary	235
Chapter 7 Conclusions & future directions	236
7.1 Conclusions and future directions	237
7.1.1 Characterisation of standardised crude extracts from the pericarp of mangosteen	238
7.1.2 Significant cytotoxicity induced by MPEE and xanthones	238
7.1.3 Cytotoxicity induced by MPEE and xanthones via multiple modes of action	240
7.1.4 Synergistic effect was found when α -mangostin was combined with another xanthone.....	242
7.1.5 Anti-metastatic activity	244
7.2 Overall conclusion	245
References	249

Appendix	284
A1 Stock solutions.....	285
A2 Identification and quantification of xanthenes in the mangosteen pericarp ethanol extract.....	287
A2.1 HPLC profile of mangosteen pericarp ethanol extract.....	287
A2.2 Molecular weight and composition of xanthenes in the mangosteen pericarp ethanol extract.....	288
A3 Mycoplasma detection using PCR.....	288
A3.1 Master mix and primer sequences for PCR.....	288
A3.2 Result for the mycoplasma test	289
A4 Cell growth curve as determined by the Trypan Blue assay over the period of 144 h.....	289
A5 Comparison of the MTT and Crystal Violet assay	290
A6 Cytotoxicity of 5-FU and DTIC on human skin cell lines.....	291
A7 One example of histogram for cell cycle analysis	292
A8 Supplementary data for apoptosis analysis.....	293
A8.1 Late apoptotic or necrotic cell population after treatment with xanthenes in two skin cancer cell lines.....	293
A8.2 One example of dot plot for apoptosis analysis	294
A9 Principle of caspase 3/7, 8, and 9 assays	295
A10 One example of dot plot for the mitochondrial membrane potential detection assay	296
A11 Supplementary data for qRT-PCR.....	297
A11.1 Efficacy of DNase treatment	297
A11.2 Detection of genomic DNA contamination by PCR	297
A11.3 Comparison of three different commercial master mixes	298
A11.4 Optimisation of qRT-PCR conditions	298
A11.5 Verification of PCR product size by running agarose gel.....	299
A11.6 Stability of housekeeping gene (β -actin) expression.....	300
A11.7 Reproducibility of qRT-PCR.....	301
A11.8 One example of qRT-PCR standard curve.....	301
A11.8.1 Standard curve.....	301
A11.8.2 Amplification efficiency (AE)	301
A11.9 One example of raw data of qRT-PCR standard curve	302
A11.10 qRT-PCR melt curve for each gene.....	303
A12 Cytotoxicity of α -mangostin at low concentrations on A-431 and SK-MEL-28 cells.....	307

List of Tables

Table 1-1.....	10
Table 1-2.....	16
Table 1-3.....	16
Table 1-4.....	25
Table 1-5.....	30
Table 1-6.....	34
Table 1-7.....	38
Table 1-8.....	41
Table 1-9.....	45
Table 1-10.....	53
Table 1-11.....	57
Table 1-12.....	61
Table 1-13.....	66
Table 2-1.....	75
Table 2-2.....	78
Table 2-3.....	88
Table 2-4.....	90
Table 3-1.....	101
Table 3-2.....	118
Table 3-3.....	126
Table 4-1.....	139
Table 4-2.....	142
Table 4-3.....	142
Table 4-4.....	151
Table 4-5.....	152
Table 5-1.....	190
Table 5-2.....	191
Table 5-3.....	202
Table 7-1.....	248

List of Figures

Figure 1-1	2
Figure 1-2	3
Figure 1-3	6
Figure 1-4	9
Figure 1-5	13
Figure 1-6	15
Figure 1-7	19
Figure 1-8	20
Figure 1-9	22
Figure 1-10	26
Figure 1-11	40
Figure 1-12	44
Figure 1-13	63
Figure 1-14	64
Figure 1-15	68
Figure 1-16	71
Figure 2-1	86
Figure 2-2	86
Figure 2-3	89
Figure 3-1	102
Figure 3-2	111
Figure 3-3	113
Figure 3-4	115
Figure 3-5	117
Figure 3-6	120
Figure 3-7	122
Figure 3-8	123
Figure 3-9	125
Figure 4-1	134
Figure 4-2	150
Figure 4-3	154
Figure 4-4	157
Figure 4-5	158
Figure 4-6	159
Figure 4-7	161
Figure 4-8	163
Figure 4-9	165
Figure 4-10	166
Figure 4-11	168
Figure 4-12	169
Figure 4-13	170
Figure 4-14	171
Figure 4-15	172
Figure 4-16	175
Figure 4-17	179
Figure 5-1	193
Figure 5-2	193

Figure 5-3	197
Figure 5-4	201
Figure 5-5	204
Figure 5-6	205
Figure 5-7	207
Figure 5-8	208
Figure 6-1	220
Figure 6-2	223
Figure 6-3	224
Figure 6-4	226
Figure 6-5	228
Figure 6-6	229
Figure 7-1	246